You know that 100% of the patients on average had 36% slowing. You know that of that 100%, 71% had 49% slowing. You know that of that 71%, roughly 50% (or 35% of the 100%) had ~85% slowing <--these are the patients missing the COL24A1 sub variant . So, work your way back and you can see that roughly 83% of all the benefit was experienced by 35% of the total. The rest of the WT with the sub variant experienced only a 14% reduction in progression. And the non-WT experienced 4% reduction in progression.
These last 2 categories of patients - the WT with the sub variant and the non-WT - essentially did not have clinically meaningful reduction in progression.
But, the WT without the sub-variant experienced their Alzheimer's being brought to a screeching halt.
This is, IMO, huge. If the EMA and FDA agree with this conclusion then approval is a no-brainer and it would essentially be mandatory to Rx 2-73 to ~4 million patients in the US and Europe. There would be zero competition from any company for 35% of AD patients.
Market Data 
Markets 
